TY - JOUR
T1 - Pericardial effusion after pediatric hematopoietic cell transplant
AU - Aldoss, Osamah
AU - Gruenstein, Daniel H.
AU - Bass, John L.
AU - Steinberger, Julia
AU - Zhang, Yan
AU - Defor, Todd E.
AU - Tolar, Jakub
AU - Verneris, Michael R.
AU - Orchard, Paul J.
PY - 2013/5
Y1 - 2013/5
N2 - PE can occur following HCT. However, the incidence, etiology, risk factors, and treatment remain unclear. We performed a retrospective study evaluating 355 pediatric recipients of HCT treated at a single institution between January 2005 and August 2010. No cases of PE were identified in the autologous HCT (auto-HCT) recipients (0/43), while 19% (57/296) of allogeneic HCT (allo-HCT) developed PE. Among the 57 PE patients, 40 (70%) were males; the median age at transplantation was 6.6 yr (0.1-17.3 yr). Thirty-six patients (63%) had significant PE with 23 patients (40%) treated by pericardiocentesis, and 19 (33%) experiencing recurrent PE. OS rates for patients who developed PE were 84% at 100 days and 65% at three yr after HCT. Risk factors associated with PE on multivariate analysis included myeloablative conditioning (p = 0.01), delayed neutrophil engraftment (p < 0.01), and CMV + serostatus of the recipient (p = 0.03). Recipients with non-malignant diseases were significantly less likely to die after development of PE (p = 0.02 and 0.004 when comparing with standard and high-risk diseases, respectively). In summary, PE is a common and significant complication of pediatric allo-HCT. Prospective studies are needed to better determine the etiology and optimal method of PE treatment after HCT.
AB - PE can occur following HCT. However, the incidence, etiology, risk factors, and treatment remain unclear. We performed a retrospective study evaluating 355 pediatric recipients of HCT treated at a single institution between January 2005 and August 2010. No cases of PE were identified in the autologous HCT (auto-HCT) recipients (0/43), while 19% (57/296) of allogeneic HCT (allo-HCT) developed PE. Among the 57 PE patients, 40 (70%) were males; the median age at transplantation was 6.6 yr (0.1-17.3 yr). Thirty-six patients (63%) had significant PE with 23 patients (40%) treated by pericardiocentesis, and 19 (33%) experiencing recurrent PE. OS rates for patients who developed PE were 84% at 100 days and 65% at three yr after HCT. Risk factors associated with PE on multivariate analysis included myeloablative conditioning (p = 0.01), delayed neutrophil engraftment (p < 0.01), and CMV + serostatus of the recipient (p = 0.03). Recipients with non-malignant diseases were significantly less likely to die after development of PE (p = 0.02 and 0.004 when comparing with standard and high-risk diseases, respectively). In summary, PE is a common and significant complication of pediatric allo-HCT. Prospective studies are needed to better determine the etiology and optimal method of PE treatment after HCT.
KW - delayed engraftment
KW - hematopoietic cell transplant
KW - myeloablative conditioning
KW - pericardial effusion
UR - http://www.scopus.com/inward/record.url?scp=84876697672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876697672&partnerID=8YFLogxK
U2 - 10.1111/petr.12062
DO - 10.1111/petr.12062
M3 - Article
C2 - 23464863
AN - SCOPUS:84876697672
SN - 1397-3142
VL - 17
SP - 294
EP - 299
JO - Pediatric transplantation
JF - Pediatric transplantation
IS - 3
ER -